UCB Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jean-Christophe Tellier

Chief Executive Officer (CEO)

€5.8m

Compensación total

Porcentaje del salario del CEO	21.2%
Permanencia del CEO	8.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jean-Christophe Tellier en comparación con los beneficios de UCB?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m
Sep 30 2017	n/a	n/a	€708m
Jun 30 2017	n/a	n/a	€664m
Mar 31 2017	n/a	n/a	€604m
Dec 31 2016	€5m	€987k	€543m

Compensación vs. Mercado: La compensación total ($USD6.33M) de Jean-Christophe está en línea con el promedio de empresas de tamaño similar en el mercado Swiss ($USD4.72M).

Compensación vs. Ingresos: La compensación de Jean-Christophe ha sido consistente con los resultados de la empresa en el último año.

CEO

Jean-Christophe Tellier (63 yo)

8.3yrs

Permanencia

€5,808,530

Compensación

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Christophe Tellier	CEO & Executive Director	8.3yrs	€5.81m	sin datos
Sandrine Dufour	Executive VP & CFO & Chief Corporate Development	2.8yrs	sin datos	sin datos
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	3.6yrs	sin datos	sin datos
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	5.5yrs	sin datos	sin datos
William Silbey	Executive VP & General Counsel	4.1yrs	sin datos	sin datos
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	3.2yrs	sin datos	sin datos
Iris Low-Friedrich	Executive VP	15.1yrs	sin datos	sin datos
Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	8.2yrs	sin datos	sin datos
Charl van Zyl	Executive VP of Neurology Solutions & Head of EU/International	3.6yrs	sin datos	sin datos
Caroline Vancoillie	Chief Accounting Officer	10.1yrs	sin datos	sin datos
Antje Witte	Head of Investor Relations	13.3yrs	sin datos	sin datos
Gwendoline Ornigg	Head of Global Communication	no data	sin datos	sin datos

5.5yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de UNC es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Christophe Tellier	CEO & Executive Director	9yrs	€5.81m	sin datos
Gerhard Mayr	Honorary Chairman	no data	€70.00k	sin datos
Mark Eyskens	Honorary Chairman	18.3yrs	€15.50k	sin datos
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	sin datos
Albrecht De Graeve	Director	13yrs	€86.00k	sin datos
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	sin datos
Diégo du de Bergendal	Honorary Chairman	2yrs	€87.50k	sin datos
Karel Boone	Honorary Chairman	no data	€49.00k	sin datos
Jonathan Peacock	Independent Chair of the Board	2yrs	€157.17k	sin datos
Charles-Antoine Emmanuel Janssen	Director	11yrs	€108.50k	sin datos
Jonkheer van Rijckevorsel	Director	9yrs	€86.00k	sin datos
Fiona du Monceau	Vice-Chair of the Board	2yrs	€159.83k	sin datos

9.0yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de UNC se considera experimentada (9 años de antigüedad promedio).

UCB Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

Investor sentiment deteriorated over the past week

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad